Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Material Agreement (Aug 17, 2026)

Reports
Material Agreements·Other Events·Exhibits & Filings
Filing Date
Filed August 17, 2026
Period End
August 13, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Aug ’21Aug ’21
  3. Material agreement8-K · Mar ’23Mar ’23
  4. Material agreement8-K · Jan ’26Jan ’26

Summary

Summary of the 8-K filed August 17, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed this Form 8-K to disclose a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P.

The Company entered into an Underwriting Agreement dated August 13, 2026 with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as representatives of the underwriters, with the shares priced at $78.00a per share. The Company will not receive any proceeds from the sale of the shares, which is expected to complete on August 17, 2026. The offering was made under the Company's effective automatic shelf registration statement on Form S-3ASR (File No. 333-297701), with a prospectus dated July 24, 2026 and a prospectus supplement dated August 13, 2026, filed August 14, 2026.

The Company issued a launch press release on August 13, 2026 and a pricing press release on August 14, 2026, which describes the offering as oversubscribed and as diversifying the institutional shareholder base. For investors, the transaction is a secondary sale by an existing holder and does not involve new capital raised by the Company. The filing includes the Underwriting Agreement, a legal opinion from Goodwin Procter LLP, and the related press releases as exhibits.

Key Highlights

  1. Secondary offering of 5,000,000 shares of common stock by selling stockholder KKR Genetic Disorder L.P., priced at $78.00 per share.
  2. BridgeBio Pharma, Inc. will not receive any proceeds from the sale of the shares.
  3. Underwriting Agreement dated August 13, 2026 with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC as representatives of the underwriters.
  4. Sale of the shares is expected to be completed on August 17, 2026.
  5. Offering made under the effective Form S-3ASR shelf registration statement (File No. 333-297701), with a prospectus dated July 24, 2026 and a prospectus supplement dated August 13, 2026.
  6. Pricing press release on August 14, 2026 describes the offering as oversubscribed and states it supports the evolution of the shareholder base toward further high-quality, long-term ownership.
  7. Filing includes a legal opinion from Goodwin Procter LLP regarding the legality of the shares sold by the selling stockholder.

Frequently Asked Questions

  1. Does this offering bring new capital to BridgeBio Pharma?

    No. The filing states that the Company is not selling any shares and will not receive any of the proceeds from the offering, which consists entirely of shares sold by the selling stockholder, KKR Genetic Disorder L.P.

  2. At what price were the shares offered?

    The shares were offered at a price to the public of $78.00 per share, as stated in the Underwriting Agreement described in the filing.

  3. How many shares are being sold and by whom?

    5,000,000 shares of BridgeBio Pharma common stock, par value $0.001 per share, are being sold by the selling stockholder KKR Genetic Disorder L.P.

  4. When is the offering expected to close?

    The filing states that the sale of the shares is expected to be completed on August 17, 2026, subject to customary closing conditions as described in the pricing press release.

  5. Under what registration was the offering made?

    The offering was made pursuant to the Company's effective automatic shelf registration statement on Form S-3ASR (File No. 333-297701), including the prospectus dated July 24, 2026, as supplemented by a prospectus supplement dated August 13, 2026, filed on August 14, 2026.